Basic Information
CellPoint B.V. enables clinicians to treat hematologic malignancies by redirecting patients' immune cells at the point of care, aiming to provide affordable and readily available CAR-T therapy for all patients in need, focusing on quality and patient safety while reducing treatment time and costs through point-of-care automation.
CellPoint B.V.
SouthHolland,Netherlands
less than 15 people
January 01, 2018
info@cellpoint.bio

